Cross-source consensus on what matters today in genetics and genomics — drawn from 16 trusted public sources including NHGRI, the CDC, NHS England, Genomics England, the PHG Foundation, the Wellcome Sanger Institute, and peer-reviewed open-access journals.
Last updated: · browse archive
Full trial results presented at ESMO 2026 show intismeran combined with pembrolizumab reduced disease recurrence significantly versus standard treatment alone in resected high-risk melanoma.
Zanvastro has received FDA approval for Alexander disease, a devastating ultra-rare neurological disorder, marking the culmination of more than 30 years of scientific work on this leukodystrophy.
A bioRxiv preprint using orthogonal CRISPR platforms and genome-wide screens reports a previously uncharacterised link between RNA N6-methyladenosine marks and de novo DNA methylation, with implications for understanding epigenetic memory.
Early-phase data presented at ESMO 2026 show a high response rate for vopimetostat plus a RAS inhibitor in patients whose pancreatic tumours carry a specific genomic deletion.
Alnylam Pharmaceuticals says its investigational RNAi therapy brezosiran showed promising signals in an early study, adding to a competitive landscape of gene-silencing strategies for Huntington's disease.
Researchers have used a halide-sensitive YFP quenching assay to functionally characterise known BEST1 variants, supporting variant classification for an investigational gene therapy programme.
A meta-analysis published in PLOS Genetics identifies genetic associations with cardiometabolic traits in people of Hawaiian and Samoan ancestry, groups largely absent from prior large-scale genomic studies.
New ESMO presentations and pipeline announcements signal the next phase of the personalised mRNA cancer vaccine programme beyond melanoma.
A newly characterised protective variant appears to block harmful protein accumulation in the brains of high-genetic-risk individuals who remain cognitively sharp into their eighties.
A preprint describes a genome-scale base-editing screen in yeast that assigned growth effects to more than 18,000 variants across coding and non-coding regions, offering a framework for understanding variant consequence at scale.
About Genetic Current
Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.
Join the Evagene Alpha Waiting List